GV notched up an exit as cancer therapy developer Monte Rosa Therapeutics priced an upsized initial public offering at the top of its range.
US-based small molecule drug developer Monte Rosa Therapeutics went public yesterday in a $222m initial public offering representing an exit for internet and technology group Alphabet’s GV unit.
The company increased the number of shares in the offering from 9.7 million to 11.7 million and priced them at the top of the IPO’s $17 to $19 range. They rose to $21.18 on their first day of trading on the Nasdaq Global Select Market, giving it a market capitalisation of…
